Buprenorphine treatment for opioid use disorder: recent progress

References

• World_Health_Organization. Information sheet on opioid overdose; 2018 [cited 2019 May]. Available from: https://www.who.int/substance_abuse/information-sheet/en/
   Google Scholar
• Eurosurveillance editorial t. The european monitoring centre for drugs and drug addiction publishes the european drug report 2013: trends and developments. Euro surv: bulletin européen sur les maladies transmissibles. 2013;18(22)
   Google Scholar
• Shei A, Hirst M, Kirson NY, et al. Estimating the health care burden of prescription opioid abuse in five European countries. Clinicon Econ Outcomes Res. 2015;7:477.
   PubMed Web of Science ®Google Scholar
• Welfare AIoHa. National opioid pharmacotherapy statistics [NOPSAD]; 2016 [Cited 2019 Apr]. Available from: https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/nopsad-2016/data
   Google Scholar
• Australian_Bureau_of_Statistics. Causes of death, Australia; 2016 [cited 2019 May]. Available from: https://www.abs.gov.au/ausstats/[email protected]/Lookup/by%20Subject/3303.0~2016~Main%20Features~Drug%20Induced%20Deaths%20in%20Australia~6
   Google Scholar
• O’Donnell JK. Deaths involving Fentanyl, Fentanyl analogs, and U-47700-10 States, July-December 2016. MMWR Morb Mortal Wkly Rep. 2017;66(43):1197–1202.
   PubMed Web of Science ®Google Scholar
• Seth P, Scholl L, Rudd RA, et al. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. Morbidity Mortality Weekly Rep. 2018;67(12):349.
   PubMed Web of Science ®Google Scholar
• Jones CM, Campopiano M, Baldwin G, et al. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–e63.
   PubMed Web of Science ®Google Scholar
• Florence C, Luo F, Xu L, et al. The economic burden of prescription opioid overdose, abuse and dependence in the United States, 2013. Med Care. 2016;54(10):901.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1564–1574.
   PubMed Web of Science ®Google Scholar
• Hser Y-I, Evans E, Grella C, et al. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015;23(2):76–89.
   PubMed Web of Science ®Google Scholar
• Fischer B, Oviedo-Joekes E, Blanken P. et al. Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. J Urban Health. 2007;84(4):552–562.
   PubMed Web of Science ®Google Scholar
• Haasen C, Verthein U, Degkwitz P, et al. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2007;191(1):55–62.
   PubMedGoogle Scholar
• Uchtenhagen A, Dobler-Mikola A, Steffen T, et al. Prescription of narcotics for heroin addicts: main results of the Swiss national cohort study. Vol. 1999. Zurich: Institute of Social and Preventative Medicine; 1999
   Google Scholar
• Strang J, Marsden J, Cummins M, et al. Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6‐month outcome. Addiction. 2000;95(11):1631–1645.
   PubMed Web of Science ®Google Scholar
• Van Den Brink W, Hendriks VM, Blanken P, et al. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. Bmj. 2003;327(7410):310.
   PubMed Web of Science ®Google Scholar
• Schechter M, Oviedo-Joekes E, Guh D, et al. North american opiate medication initiative (NAOMI): multi-centre, randomized controlled trial of heroin-assisted therapy for treatment-refractory injection opiate users. Canada: Canadian Institutes of Health Research. 2006.
   Google Scholar
• March JC, Oviedo-Joekes E, Perea-Milla E, et al. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat. 2006;31(2):203–211.
   PubMed Web of Science ®Google Scholar
• Eder H, Jagsch R, Kraigher D, et al. Comparative study of the effectiveness of slow‐release morphine and methadone for opioid maintenance therapy. Addiction. 2005;100(8):1101–1109.
   PubMed Web of Science ®Google Scholar
• Clark N, Khoo K, Lintzeis N, et al. A randomized trial of once-daily slowrelease oral morphine versus methadone for heroin dependence. Drug Alcohol Depend. 2002;66(1):S33.
   Google Scholar
• Giacomuzzi S, Kemmler G, Ertl M, et al. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants. Subst Use Misuse. 2006;41(2):223–244.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta‐analysis of cohort studies. Addiction. 2011;106(1):32–51.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–145.
   PubMed Web of Science ®Google Scholar
• Williams AR, Nunes EV, Bisaga A, et al. Developing an opioid use disorder treatment cascade: A review of quality measures. J Subst Abuse Treat. 2018;91:57–68.
   PubMed Web of Science ®Google Scholar
• Timko C, Schultz NR, Cucciare MA, et al. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22–35.
   PubMed Web of Science ®Google Scholar
• Jarvis BP, Holtyn AF, Subramaniam S, et al. Extended‐release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113(7):1188–1209.
   Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. bmj. 2017;357:j1550.
   PubMed Web of Science ®Google Scholar
• Gossop M, Marsden J, Stewart D, et al. The national treatment outcome research study (NTORS): 4–5 year follow‐up results. Addiction. 2003;98(3):291–303.
   PubMed Web of Science ®Google Scholar
• Eastwood B, Strang J, Marsden J. Effectiveness of treatment for opioid use disorder: a national, five-year, prospective, observational study in England. Drug Alcohol Depend. 2017;176:139–147.
   PubMed Web of Science ®Google Scholar
• Breen CT, Fiellin DA. Buprenorphine supply, access, and quality: where we have come and the path forward. J Law Med Ethics. 2018;46(2):272–278.
   PubMed Web of Science ®Google Scholar
• Kraus ML, Alford DP, Kotz MM, et al. Statement of the american society of addiction medicine consensus panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med. 2011;5(4):254–263.
   PubMed Web of Science ®Google Scholar
• SAMHSA. Buprenorphine waiver management; 2000 [cited 2018 Nov]. Available from: https://www.samhsa.gov/programs-campaigns/medication-assisted-treatment/training-materials-resources/buprenorphine-waiver
   Google Scholar
• SAMSHA/HHS. Medication assisted treatment for opioid use disorders; 2016 [cited 2018 Nov]. Available from: https://www.federalregister.gov/documents/2016/07/08/2016-16120/medication-assisted-treatment-for-opioid-use-disorders
   Google Scholar
• Orman JS, Keating GM. Spotlight on buprenorphine/naloxone in the treatment of opioid dependence. CNS Drugs. 2009;23(10):899–902.
   PubMed Web of Science ®Google Scholar
• Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001;297(2):688–695.
   PubMed Web of Science ®Google Scholar
• Matthes HW, Maldonado R, Simonin F, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene. Nature. 1996;383(6603):819.
   PubMed Web of Science ®Google Scholar
• Filliol D, Ghozland S, Chluba J, et al. Mice deficient for δ-and μ-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet. 2000;25(2):195.
   PubMed Web of Science ®Google Scholar
• Spanagel R, Herz A, Shippenberg TS. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem. 1990;55(5):1734–1740.
   PubMed Web of Science ®Google Scholar
• Bodkin JA, Zornberg GL, Lukas SE, et al. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49–57.
   PubMed Web of Science ®Google Scholar
• Hara N, Minami T, Okuda‐Ashitaka E, et al. Characterization of nociceptin hyperalgesia and allodynia in conscious mice. Br J Pharmacol. 1997;121(3):401–408.
   PubMed Web of Science ®Google Scholar
• Lutfy K, Eitan S, Bryant CD, et al. Buprenorphine-induced antinociception is mediated by μ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci. 2003;23(32):10331–10337.
   PubMed Web of Science ®Google Scholar
• Volpe DA, Tobin GAM, Mellon RD, et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol. 2011;59(3):385–390.
   PubMed Web of Science ®Google Scholar
• Boas R, Villiger J. Clinical actions of fentanyl and buprenorphine: the significance of receptor binding. Br J Anaesth. 1985;57(2):192–196.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569–580.
   PubMed Web of Science ®Google Scholar
• Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. BJA. 2006;96(5):627–632.
   Google Scholar
• Martin WR, Eades C, Thompson J, et al. The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976;197(3):517–532.
   PubMed Web of Science ®Google Scholar
• Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70(2):S39–S47.
   PubMedGoogle Scholar
• Ohtani M, Kotaki H, Sawada Y, et al. Comparative analysis of buprenorphine-and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther. 1995;272(2):505–510.
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Johanson C-E, Moody DE, et al. Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28(11):2000.
   PubMed Web of Science ®Google Scholar
• Greenwald M, Johanson C-E, Bueller J, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry. 2007;61(1):101–110.
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend. 2014;144:1–11.
   PubMed Web of Science ®Google Scholar
• Fareed A, Vayalapalli S, Casarella J, et al. Effect of buprenorphine dose on treatment outcome. J Addict Dis. 2012;31(1):8–18.
   PubMed Web of Science ®Google Scholar
• FDA. New drug applications Subutex and suboxone; 2002 [cited 2018 Nov]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/20732,20733ltr.pdf
   Google Scholar
• BioDelivery Sciences International I. Bunavail prescribing information 2014 [ updated 2 2018; cited 2018 Nov]. Available from: http://www.bunavail.com/assets/pdf/BUNAVAIL_Full_Prescribing_Information.pdf
   Google Scholar
• Mozurkewich EL, Rayburn WF. Buprenorphine and methadone for opioid addiction during pregnancy. Obstet Gynecol Clin. 2014;41(2):241–253.
   PubMed Web of Science ®Google Scholar
• Administration USFaD. Opioid use disorder: endpointsfor demonstrating effectiveness of drugs for medication-assisted treatment guidance for industry; 2018 [cited 2019 Jan]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM615743.pdf
   Google Scholar
• FDA. FDA approves first generic versions of Suboxone sublingual film; 2018 [cited 2018 Nov]. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm610807.htm
   Google Scholar
• Schuh KJ, Johanson C-E. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend. 1999;56(1):55–60.
   PubMed Web of Science ®Google Scholar
• Orexo US I. Zubsolv prescribing information 2018 [cited 2018 Nov]. Available from: https://www.zubsolv.com/wp-content/uploads/2015/01/ZubsolvFullPrescribingInformation.pdf
   Google Scholar
• Jönsson MFA, Tiberg C. A novel buprenorphine/naloxone tablet formulation for the treatment of opioid dependence[poster]. 44th Annual Medical-Scientific Conference of the American Society of Addiction Medicine; 2013 Apr 25-28; Chicago.
   Google Scholar
• Webster L, Hjelmström P, Sumner M, et al. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: a randomized trial. J Addict Dis. 2016;35(4):325–338.
   PubMed Web of Science ®Google Scholar
• Strain EC, Stoller K, Walsh SL, et al. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berl). 2000;148(4):374–383.
   PubMed Web of Science ®Google Scholar
• Fischer A, Jönsson M, Hjelmström P. Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers. Drug Dev Ind Pharm. 2015;41(1):79–84.
   PubMed Web of Science ®Google Scholar
• IndiviorPLC. Suboxone prescribing information 2018 [cited Dec 2018]. Available from: https://www.suboxone.com/content/pdfs/prescribing-information.pdf
   Google Scholar
• Lopatko OV, White JM, Huber A, et al. Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. Drug Alcohol Depend. 2003;69(3):317–322.
   PubMed Web of Science ®Google Scholar
• Chawarski MC, Moody DE, Pakes J, et al. Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms. J Subst Abuse Treat. 2005;29(4):307–312.
   PubMed Web of Science ®Google Scholar
• Cone EJ,Dickerson S, Darwin W, et al., editors. Elevated drug saliva levels suggest a “depot-like” effect in subjects treated with sublingual buprenorphine.Problems of Drug Dependence 1990 Proceeding of the 52nd Annual Scientific Meeting;1990Jun;Richmond, Virginia.
   Google Scholar
• Johanson C-E, Arfken CL, Di Menza S, et al. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2012;120(1):190–195.
   PubMed Web of Science ®Google Scholar
• Auriacombe M, Fatséas M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict. 2004;13 Suppl 1(S1):SS17-S28.
   Google Scholar
• Jenkinson RA, Clark NC, Fry CL, et al. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?. Addiction. 2005;100(2):197–205.
   PubMed Web of Science ®Google Scholar
• Aitken CK, Higgs PG, Hellard ME. Buprenorphine injection in Melbourne, Australia—an update. Drug Alcohol Rev. 2008;27(2):197–199.
   PubMed Web of Science ®Google Scholar
• Lavonas EJ, Banner W, Bradt P, et al. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children. J Pediatr. 2013;163(5):1377–1383. e3.
   PubMed Web of Science ®Google Scholar
• Das NG, Das SK. Development of mucoadhesive dosage forms of buprenorphine for sublingual drug delivery. Drug Deliv. 2004;11(2):89–95.
   PubMed Web of Science ®Google Scholar
• Vasisht N, Stark J, Bai SA, et al., editors. Buprenorphine-naloxone buccal film has a relative buprenorphine bioavailability approximately twice that of buprenorphine-naloxone sublingual tablet. Poster présenté lors de l’American Society of Addiction Medicine 45th Annual Conference, Orlando, FL; 2014.
   Google Scholar
• Sullivan JG, Webster L. Novel buccal film formulation of buprenorphine-naloxone for the maintenance treatment of opioid dependence: a 12-week conversion study. Clin Ther. 2015;37(5):1064–1075.
   PubMed Web of Science ®Google Scholar
• Soper R, Appajosyula S, Deximo C. Decline in buprenorphine/naloxone prescriptions in a state medicaid population following formulary conversion from suboxone to bunavail [journal article]. Adv Ther. 2018 April 01;35(4):457–466. .
   PubMed Web of Science ®Google Scholar
• Lanier RK, Umbricht A, Harrison JA, et al. Evaluation of a transdermal buprenorphine formulation in opioid detoxification. Addiction. 2007;102(10):1648–1656.
   PubMed Web of Science ®Google Scholar
• Lanier RK, Umbricht A, Harrison JA, et al. Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation. Psychopharmacology (Berl). 2008;198(2):149–158.
   PubMed Web of Science ®Google Scholar
• White J, Bell J, Saunders JB, et al. Open-label dose-finding trial of buprenorphine implants (Probuphine)® for treatment of heroin dependence. Drug Alcohol Depend. 2009;103(1–2):37–43.
   PubMed Web of Science ®Google Scholar
• Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. Jama. 2010;304(14):1576–1583.
   PubMed Web of Science ®Google Scholar
• Rosenthal RN, Lofwall MR, Kim S, et al. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. Jama. 2016;316(3):282–290.
   PubMed Web of Science ®Google Scholar
• BraeburnInc. Probuphine Prescribing information 2016 [cited Dec 2018]. Available from: https://probuphine.com/prescribing-information/
   Google Scholar
• FDA. Once monthly buprenorphine injection Indivior; 2017 [cited 2018 Nov]. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm587312.htm
   Google Scholar
• Nasser AF, Heidbreder C, Gomeni R, et al. A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. Clin Pharmacokinet. 2014;53(9):813–824.
   PubMed Web of Science ®Google Scholar
• Nasser AF, Greenwald MK, Vince B, et al. Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder. J Clin Psychopharmacol. 2016;36(1):18.
   PubMed Web of Science ®Google Scholar
• Haight BR, Learned SM, Laffont CM. et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2019;393(10173):778–790.
   PubMedGoogle Scholar
• IndivorInc. Safety and tolerability study of depot buprenorphine in treatment seeking subjects with opioid use disorder https://clinicaltrials.gov/2018 [cited 2019 Feb]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02510014?term=NCT02510014&rank=1
   Google Scholar
• IndiviorPLC. Sublocade prescribing information; 2018 [cited 2018 Dec]. Available from: https://www.sublocade.com/Content/pdf/prescribing-information.pdf
   Google Scholar
• Tiberg F, Johnsson M. Drug delivery applications of non-lamellar liquid crystalline phases and nanoparticles. J Drug Delivery Sci Technol. 2011;21(1):101–109.
   Web of Science ®Google Scholar
• Tiberg F, Johnsson M, Jankunec M, et al. Phase behavior, functions, and medical applications of soy phosphatidylcholine and diglyceride lipid compositions. Chem Lett. 2012;41(10):1090–1092.
   Web of Science ®Google Scholar
• Camurus AB LS. Buvidal summary of product characteristics; 2018 [cited 2019 Jun]. Available from: https://www.buvidal.eu/wp-content/uploads/2019/02/Weekly-Buvidal-SmPC.pdf
   Google Scholar
• Albayaty M, Linden M, Olsson H, et al. Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label Phase 1 study. Adv Ther. 2017;34(2):560–575.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Comer SD, Lofwall MR, et al. Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):894–902.
   PubMed Web of Science ®Google Scholar
• Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial. JAMA Intern Med. 2018;178(6):764–773.
   PubMed Web of Science ®Google Scholar
• Frost M, Bailey GL, Lintzeris N, et al. Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder. Addiction. 2019:1–11. https://doi.org/10.1111/add.14636.
   PubMedGoogle Scholar
• Stanos SP, Bruckenthal P, Barkin RL, editors. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clinic Proceedings. 2012;87(7):683–694.
   Google Scholar
• Packhaeuser C, Schnieders J, Oster C, et al. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm. 2004;58(2):445–455.
   PubMed Web of Science ®Google Scholar
• Carter JA, Dammerman R, Frost M. Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder. J Med Econ. 2017;20(8):893–901.
   PubMed Web of Science ®Google Scholar
• Roozen HG, de Waart R. van den Brink W. Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery. Eur Addict Res. 2007;13(4):201–206.
   PubMed Web of Science ®Google Scholar
• Baser O, Chalk M, Fiellin DA, et al. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011;17(8):S235.
   PubMedGoogle Scholar
• Coleman CI, Limone B, Sobieraj DM. et al. Dosing frequency and medication adherence in chronic disease. J Managed Care Pharm. 2012;18(7):527–539.
   Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310.
   PubMed Web of Science ®Google Scholar
• Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74(6):568–575.
   PubMed Web of Science ®Google Scholar
• Kenney SR, Anderson BJ, Bailey GL, et al. Buprenorphine treatment formulations: preferences among persons in opioid withdrawal management. J Subst Abuse Treat. 2018;94:55–59.
   PubMed Web of Science ®Google Scholar
• Hedrich D, Alves P, Farrell M, et al. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction. 2012;107(3):501–517.
   PubMed Web of Science ®Google Scholar
• Carroll KM, Weiss RD. The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry. 2016;174(8):738–747.
   PubMed Web of Science ®Google Scholar
• Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–1246.
   PubMed Web of Science ®Google Scholar
• Ling W, Hillhouse M, Ang A, et al. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction. 2013;108(10):1788–1798.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013;126(1):74.e11-74. e17.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine–naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365–374.
   PubMed Web of Science ®Google Scholar
• Reif S, Braude L, Lyman DR, et al. Peer recovery support for individuals with substance use disorders: assessing the evidence. Psychiatric Serv. 2014;65(7):853–861.
   PubMed Web of Science ®Google Scholar
• Weintraub E, Greenblatt AD, Chang J, et al. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict. 2018;27(8):612–617.
   PubMed Web of Science ®Google Scholar
• Shi JM, Henry SP, Dwy SL, et al. Randomized pilot trial of Web-based cognitive-behavioral therapy adapted for use in office-based buprenorphine maintenance. Substance abuse. 2019:1–4. https://doi.org/10.1080/08897077.2019.1569192
   PubMedGoogle Scholar
• Mares M-L, Gustafson DH, Glass JE, et al. Implementing an mHealth system for substance use disorders in primary care: a mixed methods study of clinicians’ initial expectations and first year experiences. BMC Med Inform Decis Mak. 2016;16(1):126.
   PubMedGoogle Scholar
• FDA. Opioid use disorder: endpoints for demonstrating effectiveness of drugs for medication-assisted treatment guidance for industry; 2018 [cited 2019 Jan]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM615743.pdf
   Google Scholar